RxDoctor Payments Data

J Turner, MD

Pulmonary Disease · Knoxville, TNNPI 1114948528

Payments from drug & device makers

$4,138in general payments, 2019–2025

Across 26 payments — averaging $159.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Pulmonx Corporation$2K
  • GSK$92
  • Seagen Inc.$23
  • Insmed, Inc.$15
  • Sunovion Pharmaceuticals Inc.$15
  • plus $12 from 1 others
$5,000in research payments, 2019–2025

Across 4 payments — averaging $1250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ethicon Endo-surgery Inc.$5K

What the payments were for

  • Travel & lodging$3,22378%
  • Food & beverage$91522%

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,138 in reported general payments places this provider in the 50th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$89,551
Medicare patients
659
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate62$808,793
Trelegy ElliptaFluticasone/Umeclidin/Vilanter204$162,694
Ambrisentan40$92,804
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$28,099
Pirfenidone33$24,516
Spiriva RespimatTiotropium Bromide32$20,518
Breo ElliptaFluticasone/Vilanterol28$11,760
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$11,266
Advair HfaFluticasone Propion/Salmeterol22$7,380
Incruse ElliptaUmeclidinium Bromide24$7,344
SymbicortBudesonide/Formoterol Fumarate12$5,201
DuleraMometasone/Formoterol11$3,742
Albuterol Sulfate HfaAlbuterol Sulfate99$2,548
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$2,109
Ventolin HfaAlbuterol Sulfate20$1,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$92$181,797256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →